Compare Abeona Therapeutics Inc (ABEO) vs Honest Company Inc (HNST) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

HNST trades at $3.94, up 1.03% with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Revenue declined to $371.32M in 2025 from $378M in 2024, though gross margins improved to 33.89%. Operating cash flow strengthened to $15.12M, supporting liquidity. Analyst sentiment is mixed with 30% buy ratings amid ongoing profitability challenges.

The outlook remains cautious due to persistent net losses and revenue volatility. Investment appeal hinges on margin expansion and sustained cash flow generation. Key risks include competitive pressures in personal care and execution on growth initiatives. The stock's elevated P/E of 48.83 suggests high expectations for future earnings recovery.